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Equine  infectious  anemia  (EIA)  is  an  important  viral  infection  affecting  horses  worldwide.  The  course  of
infection  is  accompanied  generally  by  three  characteristic  stages:  acute,  chronic  and  inapparent.  There  is
no effective  EIA  vaccine  or  treatment,  and  the  control  of the  disease  is  based  currently  on  identiﬁcation
of  EIAV  inapparent  carriers  by  laboratory  tests.  Recombinant  envelope  protein  (rgp90)  was  expressed  in
Escherichia  coli  and  evaluated  via  enzyme-linked  immunosorbent  assay  (ELISA).  There  was  an excellenteywords:
quine infectious anemia
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LISA
GID
agreement  (95.42%)  between  the  ELISA  results  using  rgp90  and  agar  gel  immunodiffusion  test  results.
AGID  is  considered  the  “gold-standard”  serologic  test  for equine  infectious  anemia  (EIA). After  1160
serum  samples  were  tested,  the  relative  sensitivity  and  speciﬁcity  of  the  ELISA  were  96.1% and  96.4%,
respectively.  Moreover,  analysis  diagnostic  accuracy  of  the  ELISA  was  performed.  The  ELISA  proved  robust.
Furthermore,  good  reproducibility  was  observed  for  the  negative  controls  and,  positive  controls  for  all
plates tested.. Introduction
Equine infectious anemia (EIA) is an important viral infection
ffecting horses worldwide. The disease is most prevalent in the
arm regions of the globe where the more abundant populations of
nsect vectors may  transmit the virus among horses (Issel and Foil,
984; Issel et al., 1988a).  The course of infection is accompanied
enerally by three characteristic stages: acute, chronic and inap-
arent. In the acute stage, extensive viral replication occurs in the
eripheral and tissue macrophages. In the chronic stage, recurring
ycles of viremia are associated with febrile peaks (up to 40 ◦C) that
ersist for 3–5 days. The interval between virus cycles is irregular,
anging from weeks to months. The inapparent stage is character-
zed by the absence of the clinical signs of EIA and negligible plasma
iremia. Some affected animals die after the acute stage, but most
orses survive (over 95%) and enter an inapparent (asymptomatic)
tage (Montelaro et al., 1993). In fact, the majority of EIA cases in
he ﬁeld (EIAV natural infection) are inapparent (Montelaro et al.,
993).
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There is no effective EIA vaccine or treatment, and the con-
trol of the disease is based currently on identiﬁcation of EIAV
inapparent carriers by laboratory diagnosis (Leroux et al., 2004).
A number of different serologic tests have been developed that
mainly rely on the detection of serum antibodies to the major core
protein of EIAV, p26, in a manner similar to current assays for
HIV (Coggins and Norcross, 1970; Issel and Cook, 1993; Reis and
Leite, 1994a; Alvarez et al., 2007). The agar gel immunodiffusion
(AGID or Coggins) test and ELISA are used widely to detect p26
antibodies. Therefore, the use of only this protein decreases the
level of speciﬁcity and sensitivity of diagnosis. Issel et al. (1988b)
and Chong et al. (1991) supported the need for a more sensi-
tive diagnostic test utilizing the envelope proteins of EIAV that
would clarify the true status of those horses with equivocal or
weak positive results against a p26 core protein test. Reis et al.
(1994b) demonstrated that control of EIA focus in Brazil was  test-
dependent. The ELISA was  a more sensitive assay and it decreased
the disease eradication period. In an outbreak of EIA that occurred
in Ireland in 2006, ELISA and immunoblotting were found to be
more sensitive than AGID in detecting acute cases of EIA (Cullinane
et al., 2007). Moreover, it has been demonstrated that the levels
of speciﬁc antibody against the surface glycoproteins of EIAV in
Open access under the Elsevier OA license.persistently infected horses are 102–103 times higher than the p26-
speciﬁc antibody levels (Montelaro et al., 1984; Issel et al., 1988b;
O’Rourke et al., 1988; Rwambo et al., 1990). In fact, the predomi-
nant humoral immune responses after EIAV infection are directed
ological Methods 180 (2012) 62– 67 63
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Table 1
The nucleotide sequence and position in EIAV genome of primers used to amplify
the  proviral DNA encoding gp90 protein.
Primer Sequence (5′–3′) Gene and locationa
gp90-1 CAGTGGATCCTTCCCGGGGTGTAGA Env (5686-5700)J.K.P. Reis et al. / Journal of Vir
rimarily against gp90. Antibodies to gp90 are detectable typically
–10 days post-infection, and they reach a plateau and remain
s the predominant antibody response throughout the course of
nfection (Montelaro et al., 1984).
Some investigators have shown that neutralization antibodies
nly appear 38–87 days post-infection, and many do not reach
aximal levels until 90–148 days (Carpenter et al., 1987; O’Rourke
t al., 1988; Rwambo et al., 1990; Ball et al., 1992; Hammond et al.,
997). Indeed, the presence of anti-gp90 antibodies in the absence
f neutralizing activity at the initial stage of infection suggests that
he major immunogenic sites on the viral surface are not sensitive
o neutralization. Studies using synthetic peptides have demon-
trated that the carboxy-terminus region of the EIAV gp90 and the
IV gp120 proteins contain highly conserved and immunodomi-
ant epitopes that are reactive with non-neutralizing antibodies
Palker et al., 1988). The amino-terminus of EIAV surface gp90 has
n immunodominant domain, but although this sequence appears
o be conserved among EIAV isolates, the pattern of reactivity
ith the sera of experimentally (prototype) and naturally (wild-
ype) infected horses suggests structural and antigenic variations
etween these strains of EIAV (Payne et al., 1989).
The immunogenic contributions of the carbohydrate and pep-
ide components of gp90 have been examined by measuring
he effects of glycosidase and protease digestions on the reac-
ivity of the glycoprotein with equine immune sera (Montelaro
t al., 1984). These results indicate that the humoral immune
esponse is directed primarily against the peptide component of
he glycoprotein during a persistent EIAV infection, whereas only
inor antibody reactivity is detectable against the carbohydrate
omponents of the virus envelope proteins. The use of an EIAV
lycoprotein-based assay can provide greatly enhanced sensitivity
or an immunologic diagnosis assay. This paper describes an efﬁ-
ient system for the production of large amounts of recombinant
on-glycosylated gp90 protein that contains the carboxyl-terminus
mmunodominant region but lacks the amino-terminus region.
his recombinant protein was evaluated in an indirect ELISA to
etect speciﬁc anti-EIAV antibodies in the sera of infected equids.
. Materials and methods
.1. Extraction of proviral DNA
Provirus was obtained by the extraction of genomic DNA from
quine dermis cells infected with the EIAV cell-adapted strain
yoming. Approximately 107 infected cells in a monolayer (75 cm2
ask) were washed twice with phosphate buffered saline (PBS)
nd STE solution (0.1 M NaCl, 1 mM EDTA, 10 mM Tris–HCl pH 8.0)
efore being lysed with a solution consisting of: 500 l of STE,
50 l 20% SDS and of 20 l proteinase K (5 mg/ml), followed by
ncubation in a water bath at 56 ◦C for 18 h. Subsequently, a suspen-
ion of 80% (v/v) isopropanol (Sigma–Aldrich) was  added and then
entrifuged at 15,000 g for 30 min. The precipitated material was
esuspended in ultra-pure water, and the solution washed twice in
 mixture of phenol–chloroform and isoamylic alcohol (25:24:1),
nd the supernatant aqueous phase was recovered using a ﬁnal
ash using a mixture of chloroform–isoamylic alcohol (24:1).
odium acetate (3 M)  and absolute ethanol (Merck, Darmstadt,
ermany) were added to the solution, which was  then incubated
t −20 ◦C for 18 h. After incubation, the solution was centrifuged
or 30 min  at 14,000 g and, subsequently, the precipitated DNA was
ashed with 75 and 100% ethanol and DNA was  resuspended in
5 l ultra-pure water. DNA concentration was  estimated by UV
pectrophotometry (260 nm)  following DNA fractionation on 0.8%
garose gels stained with ethidium bromide.gp90-2 CAATCTGCAGAATTAGTCCAGTGTTAG Env (6614-6627)
a Genomic locations based on published sequences by Kawakami et al., 1987.
2.2. Ampliﬁcation of DNA by PCR
All primers were designed based on the sequence of the EIAV
gene as described by Kawakami et al. (1987) (Table 1). The PCR
mixture consisted of 10 mM Tris–HCl (pH 9.0), 50 mM KCl, 1.5 mM
MgCl2, 0.1% triton X-100, 20 mM of each dNTP, 10 pmol of each
speciﬁc primer, 200 ng of target DNA and 1 U of Taq polymerase
(Promega, USA). The reaction was  performed with 1 cycle of 2 min
at 95 ◦C, 1 min  at 37 ◦C, 1 min  at 72 ◦C, 30 cycles at 95 ◦C for 30 s,
55 ◦C for 30 s and 72 ◦C for 1 min  followed by incubation at 72 ◦C
for 15 min.
2.3. Cloning gp90 fragment into expression plasmid vector
The PCR product, which contains restriction sites for Bam-HI
and PST-I introduced by the primers, was puriﬁed (Glassmilk,
Promega, USA), digested with the aforementioned restriction
enzymes and ligated into the expression plasmid pQE-30 vector.
After inserting the plasmid into Escherichia coli M15, the posi-
tive clones were identiﬁed by PCR with pQE-30 speciﬁc primers
(for ampliﬁcation of the area corresponding to insert) being
the primer (sense) 5′-TTCATTAAAGAGGAGAAATT- 3′ and primer
(antisense) 5′- CTATCAACAGGAGTCCAAGC- 3′. All of these proce-
dures for cloning followed the manufacture’s instructions (The
QIAexpressionistTM, Qiagen, USA). The nucleotide sequence of the
cloned gp90 was  determined by an automatic sequencer (Applied
Biosystems, USA).
2.4. Production and puriﬁcation of gp90 EIAV recombinant
protein (rgp90)
Approximately 500 ml  of transformed E. coli (M-15) bacterial
culture was  grown with shaking (170 rpm) at 37 ◦C in LB medium
(10 g Bacto-tryptone, 5 g bacto-yeast extract, 5 g of NaCl) containing
100 g/ml of ampicillin and 25 g/ml of kanamycin until reaching
an OD600 of 0.6. Then, 2 mM (ﬁnal concentration) of Isopropyl--d-
thiogalactoside (IPTG) was added. After a 5-h additional incubation,
a 1 ml  aliquot was  taken for analysis by SDS-PAGE. The remain-
ing culture was centrifuged, and the cell pellet was resuspended
in 50 ml  of buffer A (0.01 M Tris–HCl pH 8.0, 0.1 M NaH2PO4, 6 M
guanidine–HCl) and stirred for 1 h (with magnetic bar at 100 rpm).
After repeated centrifugation, the supernatant was  loaded onto
a nickel chelate afﬁnity chromatography column (Hochuli et al.,
1987). The column was  washed sequentially with 20 ml  of buffer
A, 20 ml  of buffer B (8 M urea, 0.1 M NaH2PO4, 0.01 M Tris–HCl, pH
adjusted to 8.0), 20 ml  of buffer C (buffer B, pH adjusted to 6.0),
20 ml  of buffer D (buffer B, pH adjusted to 5.0) and 20 ml  of buffer
E (buffer B, pH adjusted to 4.0). Three milliliter fractions were col-
lected and analyzed by SDS-PAGE to detect gp90-expressed protein.
2.5. ELISA
ELISA evaluation of rgp90 protein was used with a panel of 1160
horse sera from the Brazilian ﬁeld. In this panel, 179 sera were posi-
tive and 981 were negative according to AGID testing (Coggins and
Norcross, 1970). Also a strong positive, weak positive and nega-
tive reference sera were used in serial twofold dilutions to deﬁne
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Fig. 1. Electrophoresis in agarose gel (ethidium bromide stained) of PCR-ampliﬁed
for the production and puriﬁcation of large amounts of rgp90 as
described above. The six histidine residues at the rgp90 N-terminal
portion introduced by a pQE-30 expression plasmid gave the pro-
tein a negatively charged polar tail that was  used for puriﬁcation in
Fig. 2. SDS-PAGE (Coomasie Blue stained) of rgp90 synthetized in Escherichia coli4 J.K.P. Reis et al. / Journal of Vir
he better dilution of serum that show the highest discrimination
etween positive and negative sera. After the best dilution of serum
as found the ELISA was conducted as follow: the rgp90 anti-
en was diluted in 50 mM sodium carbonated buffer (pH 9.6) at
0.0 g/ml, 100 l was added into each well of a 96 microplates
nd the mixture was incubated for 18 h at 4 ◦C. The plates were
hen washed twice with phosphate buffered saline (pH 7.2) con-
aining 0.05% of Tween 20 (PBS-Tween) and incubated for 1 h at
oom temperature with 5% of nonfat dried milk in PBS-Tween solu-
ion for blocking. Followed by two washes with PBS-Tween and a
ew incubation (1 h at room temperature) with test sera diluted
:50 in PBS-Tween solution. The plates were washed three times
n PBS-Tween solution, and the rabbit anti-horse IgG peroxidase
onjugate (Sigma, USA) diluted 1:7500 in PBS-Tween was  added
nd incubated for 1 h before the plates were washed three times.
 solution with the substrate o-phenylenediamine (0.5 mg/ml) and
ydrogen peroxide (0.02% ﬁnal concentration) in phosphate-citrate
uffer (pH 5.0) was added (100 l/well), and color development
as allowed to proceed for 10 min  before the reaction was  stopped
y addition of a 3 N sulfuric acid solution (40 l/well). The opti-
al density (OD) at 492 nm was read with a Titertek Multiskan
pectrophotometer (Flow Laboratory, Inc.).
.6. Quality assurance and repeatability of ELISA
The repeatability (intra-plate variability) was assessed by the
ame analyst testing two samples (negative and positive control)
our times on the same plate, on the same day. The mean and
oefﬁcients of variation (CVs) were computed using Excel 2007
Microsoft Corp, USA).
The reproducibility (inter-plate variability) of the test results
as assessed by testing two samples (negative and positive con-
rol) 20 times. The results were obtained by use of distinct lots, on
ifferent days, by different analysts. The mean and coefﬁcients of
ariation (CVs) were computed.
.7. rgp90 ELISA and AGID agreement
The agreement between the rgp90 ELISA and the AGID test was
etermined by use of a Kappa statistic with a 95% conﬁdence inter-
al, using Stata software version 10 (Stata Corp., College station, TX,
SA).
The cut-off was selected by visual inspection of frequency distri-
utions of OD for samples negative and positive by reference AGID.
his cut-off reduced the test results to positive and negative cat-
gories. After the selection of cut-off, the relative sensitivity and
peciﬁcity were estimated. Sensitivity was calculated as true pos-
tive/(true positive + false negative) whereas speciﬁcity was true
egative/(true negative + false positive). The results of calculations
ere expressed as percentages (Jacobson, 1998).
. Results
.1. Ampliﬁcation, cloning and nucleotide sequencing of rgp90
Speciﬁc primers were able to amplify a sequence of 900 bp
rom the genomic DNA (Fig. 1, lane 2). This DNA fragment was
loned into the expression vector pQE-30. Mini-preparations of the
ransformed bacteria were prepared, and the cloned fragment was
mpliﬁed by PCR with pQE-30 speciﬁc primers. The 900 bp frag-
ent obtained by PCR was consistent with the predicted size (Fig. 1,
ane 3). In order to verify that the PCR product corresponded to the
p90 gene, nucleotide sequencing was performed. The sequencing
ndicated 99.6% homology with the sequence described previously
y Kawakami et al. (1987).  In addition to the gp90 protein, which
ad four substitutions (two silent substitutions and two amino acidDNA using speciﬁc primers to target gp90 sequence. Lanes 2 and 3 present the ampli-
ﬁed  product from the genomic DNA and from the pQE-30 plasmid cloned with the
gp90 fragment, respectively. Size markers are presented in lane 1.
substitutions, Asn–Gln and Val–Ile), six histidine residues from the
plasmid pQE-30 were also incorporated at its amino-terminus.
3.2. Production and puriﬁcation of rgp90
The induced cultures over-expressed a protein with a molecular
weight around 39 kDa that was not observed in the control cultures
(Fig. 2 lanes 4 and 5). Five hundred milliliter cultures were usedand  puriﬁed in chelate chromatography. The eluted fractions were visualized in
lane 1 (residual, pH 8.0), lane 3 (buffer E, pH 4.0) and lane 2 (buffer D, pH 5.0)
containing the puriﬁed rgp90. Lanes 4 and 5 contain the extracts of transformed
bacteria induced and not induced with IPTG, respectively. Molecular weight (MW)
standards are indicated in the left margin.
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elution. The proteins obtained by this procedure, in contrast to pro-
teins eluted by Gu–HCl, can be subjected directly to SDS-PAGE or
injected into animals for immunization.
Table 2
Comparison of rgp90 ELISA and AGID test for detection of serum antibodies to EIAV.Fig. 3. rpg90 ELISA titration curves of stron
he nickel chelate afﬁnity chromatography column (Ni+). The com-
osition of fractions was analyzed by SDS-PAGE. Buffer D at pH 5.0
Fig. 2, lane 2) eluted the highly puriﬁed rgp90 from the column.
he protein (from supernatant of cultures) was ligated completely
n the matrix of the column, as no band could be seen from the
esidual fraction (Fig. 2, lane 1), and no protein was obtained at pH
.0 – buffer E (Fig. 2, lane 3). Approximately 4 mg  of rgp90, as esti-
ated using the method of Lowry et al. (1951),  could be produced
y 500-ml cultures.
.3. ELISA
The titration curves of the strong positive, weak positive and
egative sera observed in the rgp90 ELISA are presented in Fig. 3.
ood discrimination between positive and negative sera with low
ackground for normal serum was obtained when sera were diluted
:50. Based on this titration all 1160 ﬁeld sera were diluted 1:50 in
BS-Tween solution. Fig. 4 presents the rgp90 ELISA OD distribution
f the 179 positive and 981 negative sera as determined by AGID.
rom these results all sera with OD value more than 0.225 were
onsidered to be positive in rgp90 ELISA.
.4. ELISA quality assurance
.4.1. Within plate variation
The mean OD value of the negative control was 0.188 (range
.160–0.216) (mean ± 2 standard deviations) and the CV was 7.58%.
he mean OD value of the positive control was  0.692 (range
.60–0.784) (mean ± 2 standard deviations) and the CV was  6.65%.
.4.2. Reproducibility of ELISA
The mean OD value of the negative control was 0.156 (range
.084–0.228) (mean ± 2 standard deviations) and the CV was
2.37%. The mean OD value of the positive control was 0.939
range 0.521–1.148) (mean ± 2 standard deviations) and the CV was
2.24%. The standard deviation of the replicates indicates that the
gp90 ELISA is a very reproducible test.
.4.3. Kappa statistic
Using AGID as a reference test, the concordance between the
pg90 ELISA and AGID was 95.43% (kappa index = 0.83), with 1118
era having coincident results and 42 sera having discordant results
Table 2). A value of 1 indicates perfect agreement and a value oftive, weak positive and negative equid sera.
0.81–1 is considered to represent almost perfect agreement (Landis
and Kock, 1977).
The cut-off at the intersection of the two distributions of results
negative and positive resulted in rates of 3.9% false negative (FN)
and 3.6% false positive (FP) for the assay. Considering 0.225 as cut-
off value rpg90 ELISA showed relative diagnostic sensitivity and
relative diagnostic speciﬁcity of 96.1% and 96.4%, respectively.
4. Discussion
The production of native proteins from disrupted virions is
rather expensive, difﬁcult and time consuming. Moreover, the anti-
gen usually is contaminated with cell proteins that frequently are
co-puriﬁed (Sugiura et al., 1995). Thus, the synthesis of recombi-
nant antigens in bacterial systems is an efﬁcient method to produce
large amounts of viral proteins while eliminating the need to main-
tain the infectious agent itself.
The pQE-30 expression system used for the production of the
partial envelope gp90 protein of EIAV provides fast and easy one-
step puriﬁcation along with high efﬁciency. Approximately 8 mg  of
high-purity rgp90 could be obtained from 1 l of bacterial culture.
This was  approximately 30 and 3 times greater than the amount of
recombinant EIAV protein obtained by Archambault et al. (1989)
and Thomas et al. (1992),  respectively. The production of rgp90
could be optimized to scale-up the process from the laboratory to
the industrial scale.
Recombinant proteins expressed in E. coli often are found to be
insoluble and can be dissolved only with detergents or dissociating
agents such as guanidine or urea. Therefore, the process of puriﬁ-
cation used in this study permitted the use of one buffer containing
6 M guanidine–HCl to disrupt bacteria and to load the column and
another buffer that contained 8 M urea instead of 6 M Gu–HCL forTests AGID+ AGIG− Total
rgp90 ELISA+ 172 35 207
rgp90 ELISA− 7 946 953
Total 179 981 1160
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Despite the absence of an N-terminal immunodominant domain
nd carbohydrate components, the antigenicity of the rgp90 against
ositive serum was observed in immunoblotting assays (data not
hown). The ELISA using the recombinant rgp90 provided a high
evel of reproducibility on different days, suggesting robustness of
he assay. According to Jacobson (1998),  the coefﬁcients of variation
eing generally less than 20% for raw absorbance values indicates
dequate repeatability at this stage of assay development. More-
ver, the Kappa statistic revealed that the ELISA was in excellent
greement with the AGID (kappa index = 0.83) (Landis and Kock,
977). The ELISA with rgp90 differentiates between the positive
nd negative sera tested by AGID. This ability makes it an ideal
est for diagnosis screening, similar to other ELISA tests that use
he USDA-approved p26 antigen. In these cases, all ELISA positive
amples must be conﬁrmed by AGID before regulatory actions are
aken, and more accurate diagnoses have been reported by using
 combination of both tests (Issel and Cook, 1993). The different
esults obtained with AGID tests that use the p26 antigen in com-
arison with the ELISA using the rgp90 antigen can be explained
y the differing sensitivity or/and speciﬁcity of the two tests. Issel
nd Cook (1993) demonstrated that some horse sera are reactive
nly with p26 EIAV antigen in immunoblot, and they suggest that
hese results should be considered as indeterminate and not as pos-
tive, according to guidelines for diagnosis of HIV (WHO, 1999).
ven when these animals were retested at 30–60 days, reactivity
ith other viral proteins was not detected (Issel and Cook, 2004,
ssel et al., 2007). Similar results were obtained in the laboratory
here some horse sera from endemic areas with equivocal/positive
esults in AGID were reactive in ELISA (CELISA, IDEXX, Westbrook,
aine, USA) and Western blots of p26 but not rgp90 (data not
hown). However, some EIAV-infected animals have been iden-
iﬁed with very low levels of antibodies against p26 and have
een reported as false negatives by AGID tests (Issel et al., 2007).
n the current study, rgp90 ELISA presented a high sensitivity at
etecting anti-gp90 antibodies in the early days post-infection.
he animals tested positive by the 7th day post-inoculation with
IAV (Wyoming strain). The result coincided with a virus replica-
ion level associated with a temperature peak (over 40 ◦C) (data on
urrent publication).
EIA diagnosis can be improved by combining rpg90 ELISA and
GID tests. The rapidity and high sensitivity of rgp90 ELISA make
t ideal for screening suspected cases of EIA, particularly in areas
here acute cases are common (Reis et al., 1994b). Although AGID
akes 24 h to be performed and is less sensitive, it is considered to
e a good conﬁrmatory test due to its high speciﬁcity and becauseositive and 981 negative equids as determined by AGID.
it is the only method that has been shown to correlate with the
presence of virus in horse inoculation tests (Pearson et al., 1971;
Coggins et al., 1972).
Additionally, the rgp90 can be used in immunoblot tests for
EIA along with other EIAV recombinant proteins. The immunoblot
tests are usually more sensitive assays and, unlike other serological
tests, they may  detect antibody reactivity to multiple viral proteins
(Issel et al., 1999). Thus far, there is no EIAV immunoblot test com-
mercially available. Furthermore, the use of multiple serological
tests with different viral proteins may  reduce the number of false
positive and false negative results during the diagnosis of EIA.
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